How to Archive Paper vs Electronic TMF Records in Clinical Trials

Introduction: Two Paths to Regulatory Archiving

In clinical trials, managing and archiving the Trial Master File (TMF) is critical for compliance with global regulatory standards. As organizations shift from traditional paper-based systems to electronic TMFs (eTMFs), understanding how to properly archive each format—individually or in hybrid—is essential to ensure audit readiness and data integrity.

Regulatory agencies including the FDA and EMA emphasize that both paper and electronic records must remain complete, accurate, and accessible throughout their required retention period. This article explores how paper and electronic TMFs differ in archiving practices, requirements, and compliance risks.

Archiving Paper TMF Records: Physical Storage and Protection

Archiving paper TMF records involves transporting physical documents to a secure long-term storage facility. These archives must be protected from physical degradation, unauthorized access, and loss.

Key Paper Archiving Steps:

• Finalize and QC all documents before transfer
• Use acid-free boxes and clearly labeled folders
• Create an inventory index of all stored materials
• Assign a TMF archive custodian for access control
• Use barcode tracking for retrieval efficiency

Facilities should be temperature- and humidity-controlled, with fire suppression and restricted access. Archival contracts with third-party storage vendors must specify retention timelines, disaster recovery procedures, and destruction protocols.

Archiving eTMF Records: Ensuring Digital Longevity

eTMFs offer easier access, searchability, and version control, but require specific validation and file integrity safeguards when archiving digitally.

Best Practices for eTMF Archiving:

• Export documents into non-proprietary formats like PDF/A or TIFF
• Retain audit trails, metadata, and version histories
• Ensure platform compliance with 21 CFR Part 11 and EU Annex 11
• Use validated, read-only archive environments
• Implement regular backup and disaster recovery testing

Platforms such as Veeva Vault, MasterControl, and PhlexTMF offer eTMF modules with archiving capabilities. Ensure archived files remain accessible during retention—some regulators may require access up to 25 years post-trial.

For guidance on archiving SOPs and indexing templates, visit PharmaSOP.in.

Managing Hybrid TMFs: The Best (and Worst) of Both Worlds

Many clinical trial sponsors operate with a hybrid TMF—where some documents are stored electronically while others remain in paper form. While practical, this model introduces unique archiving challenges.

Best Practices for Hybrid TMF Archiving:

• Document clearly in the TMF plan which files are stored electronically vs. physically
• Ensure scanned documents are linked to original paper copies, or validate scanned images for destruction of originals
• Maintain a unified index across both formats for audit trail continuity
• Use cross-referenced folder naming conventions
• Define clear roles for both eTMF administrator and paper archive custodian

Regulators may inspect both components of a hybrid TMF simultaneously. Ensure both are synchronized, complete, and verifiable. Discrepancies between scanned and physical documents can lead to major compliance findings.

Compliance Risks in Archiving TMF Records

Regardless of the format, TMF archiving that fails to follow GCP guidelines can jeopardize trial integrity and regulatory approval. Common mistakes include:

• Lack of archiving SOPs: Many sites treat archiving as an afterthought, without defined procedures
• Unvalidated eTMF platforms: Archiving on non-compliant systems fails 21 CFR Part 11 audits
• Missing inventory logs: Paper TMFs without index records are difficult to navigate during inspections
• Inaccessible archives: Long-term archives must be retrievable even years later

As per EMA inspection reports, archival errors such as uncontrolled document destruction or expired access credentials can lead to serious findings.

Inspection Readiness: What Auditors Will Look For

Auditors will evaluate both how TMF documents are archived and how easily they can be retrieved. Whether using paper or eTMF systems, prepare for the following audit queries:

• “Where are your archived documents stored?”
• “Can you show evidence of audit trail retention for digital files?”
• “What system do you use for barcode tracking in paper archives?”
• “Do your archive facilities meet environmental and security standards?”

Prepare by conducting internal mock audits focused solely on TMF archiving practices. Validate that your SOPs, training records, and system access logs are all inspection-ready.

Key Differences Between Paper and eTMF Archiving

Conclusion: Choosing the Right Archiving Approach

Whether using paper, electronic, or hybrid TMFs, compliance starts with a well-defined archive strategy. From inventory management and SOPs to validated platforms and custodianship, the success of your TMF archiving program directly impacts your regulatory outcomes.

While eTMFs offer speed and traceability, paper archives remain common—especially in legacy trials and multi-center studies. The key is ensuring that whatever method you use, it complies with the expectations of FDA, EMA, and other authorities.

For archiving templates, scanning protocols, and audit readiness checklists, visit PharmaValidation.in.

TMF Retention Periods After a Clinical Trial: Global Guidelines Explained

Why Retaining TMF Documents Post-Trial is Critical

Clinical trial documents don’t lose relevance when a study ends. Regulatory bodies require sponsors, CROs, and sites to retain essential records for years—sometimes decades—after trial completion. This long-term retention ensures that all trial activities remain traceable, auditable, and compliant with Good Clinical Practice (GCP) standards.

Whether you’re dealing with paper-based records or an eTMF system, understanding how long to retain TMF documents is vital to staying inspection-ready and avoiding compliance pitfalls.

Overview of Global TMF Retention Guidelines

The required retention duration varies by region and regulatory authority. Here’s a summary of the most commonly referenced requirements:

Sponsors conducting multi-national trials must adhere to the longest applicable retention period across participating countries.

What Documents Must Be Retained?

Retention applies to all documents listed in ICH E6(R2) Section 8 as “essential.” These include, but are not limited to:

• Final protocol and amendments
• Investigator Brochure (IB)
• Informed Consent Forms (ICFs)
• Monitoring reports
• Site delegation logs
• Regulatory approvals and ethics committee correspondence
• Final Clinical Study Report (CSR)

The documents must remain accessible, readable, and protected from unauthorized access or deterioration for the full retention duration.

For a TMF retention checklist and audit tools, visit PharmaSOP.in.

Managing eTMF Retention for Long-Term Compliance

As more sponsors shift to electronic Trial Master Files (eTMFs), digital retention strategies are essential. Retaining eTMFs isn’t simply about storing files—it involves maintaining the entire audit trail, metadata, and file integrity for years, sometimes decades.

Best practices for eTMF retention include:

• Archiving in non-proprietary, long-term readable formats (e.g., PDF/A, TIFF)
• Retaining system-generated metadata, version history, and audit logs
• Maintaining validated infrastructure that complies with 21 CFR Part 11 and Annex 11
• Defining SOPs for eTMF system access, backup, migration, and decommissioning

For example, an eTMF archived in 2024 must still be retrievable and readable in 2049 if the trial is governed under EMA’s 25-year rule.

Who Owns TMF Retention Responsibilities?

According to ICH and FDA guidance, the sponsor holds ultimate responsibility for TMF retention, even if the trial is outsourced to a CRO.

Key assignments should include:

• Sponsor QA: Responsible for archiving policies and oversight
• CRO Document Manager: Maintains records and performs archival migration
• TMF Custodian: Maintains log of archive access, backups, and physical location

Contracts with CROs must clearly define retention timelines and responsibilities post-database lock or trial closeout.

Audit Risks During the Retention Period

Retaining TMFs isn’t enough—they must be retrievable and complete when regulators come knocking. Retention periods are subject to audit, especially in post-marketing safety reviews or follow-up inspections.

Questions inspectors may ask during TMF retention audits include:

• “Can you retrieve a final signed ICF from a trial conducted 10 years ago?”
• “Has the sponsor verified ongoing access to archived digital records?”
• “Who has access to these files and how is access logged?”

Deficiencies in document traceability or access can lead to audit findings and regulatory action.

Document Disposal After Retention Period

After the retention period expires, sponsors may initiate secure destruction. However, this must be done under formal SOPs and in line with contractual and legal obligations.

Steps include:

• Internal sign-off from QA and Legal before destruction
• Documenting the destruction process with a certificate
• Destroying both paper and digital files through validated processes
• Notifying all relevant partners, including CROs, of final archive status

Records should never be destroyed if there is an ongoing litigation, regulatory hold, or unresolved safety concern.

Conclusion: TMF Retention is More Than a Timeline

Retaining TMF documents for 2, 15, or 25 years isn’t just about holding onto files—it’s about maintaining compliance, audit readiness, and data integrity. From system validation to staff training and SOP enforcement, every aspect of the TMF lifecycle must align with retention rules.

Whether storing physical binders or cloud-based eTMFs, organizations must have a sustainable retention infrastructure in place. And that begins with a clear understanding of global regulatory expectations.

For global retention checklists, archive planning tools, and SOP templates, visit PharmaValidation.in.